ClinicalTrials.gg
CompletedNCT02045264Updated Jun 3, 2021Results posted

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

A Phase 1 interventional study of Icatibant (30 mg) in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
7th of 10
12 · median 26
Started
2014
the only one that year
Phase 1
Only one
of the 10
Registered
7th of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 7th largest by enrollment, is the only one that started in 2014, is the only one in phase 1, and was the 7th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

This is a single-dose study to evaluate the pharmacokinetics, safety, and tolerability of icatibant administered to adult Japanese subjects.

Read the detailed description

Icatibant has been studied for the treatment of acute attacks of hereditary angioedema (HAE), an autosomal dominant disorder characterized by recurrent and self-limiting episodes of edema of the skin, larynx, and gastrointestinal tract. The most serious manifestation of an HAE attack is laryngeal edema, causing obstruction of the upper airways that may lead to death by asphyxiation if undiagnosed and/or untreated.

Icatibant has been approved in over 40 countries around the world including the United States (US) and Europe for the treatment of acute attacks of hereditary angioedema (HAE) in adults. This study is being conducted to evaluate the safety and tolerability of icatibant in a Japanese population and to evaluate whether race/ethnicity impacts the pharmacokinetics of icatibant after single subcutaneous injection.

This is an open-label, single-arm study that will enroll at least 12 Japanese subjects (in order to have 12 subjects complete the study), age 18-55 years inclusive. All subjects will receive a single subcutaneous injection of 30mg icatibant. The study will be conducted at 1 site in the US. The study will consist of a Screening Period, a Treatment Period, and a Follow-Up Period.

03

Conditions studied

  • Hereditary Angioedema (HAE)

Keywords

  • Firazyr
  • Angioedema
  • Angioedemas, Hereditary
  • Vascular Diseases
  • Cardiovascular Diseases
  • Urticaria
  • Skin Diseases, Vascular
  • Skin Diseases
  • Hypersensitivity, Immediate
  • Hypersensitivity
  • Immune System Diseases
  • Genetic Diseases, Inborn
  • Icatibant
  • Anti-Inflammatory Agents, Non-Steroidal
  • Analgesics, Non-Narcotic
  • Analgesics
  • Sensory System Agents
  • Peripheral Nervous System Agents
  • Physiological Effects of Drugs
  • Pharmacologic Actions
  • Anti-Inflammatory Agents
  • Therapeutic Uses
  • Antirheumatic Agents
  • Adrenergic beta-Antagonists
  • Adrenergic Antagonists
  • Adrenergic Agents
  • Neurotransmitter Agents
  • Molecular Mechanisms of Pharmacological Action
  • Central Nervous System Agents
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female volunteers, 18 to 55 years of age, inclusive; healthy status defined as absence of findings in medical history or screening assessments
  2. Japanese; defined as born in Japan, lived outside of Japan for no more than 10 years, and having Japanese parents and Japanese maternal and paternal grandparents
  3. of 18 to 28 kg/m2, inclusive

Exclusion criteria

Exclusion Criteria:

  1. History of, or current, disease and/or abnormalities
  2. Smoking habit in excess of 5 cigarettes per day or the equivalent within 30 days of Day 1 or inability to refrain from smoking during the study confinement period
  3. Subject has current abnormal thyroid function, as defined as abnormal screening thyroid stimulating hormone (TSH) and free thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 12 weeks is permitted
  4. History of drug allergy or other allergy that, in the opinion of the investigator, contraindicates participation
  5. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. (1 alcohol unit =1 beer or =1 wine (5oz/150mL) or =1 liquor (1.5oz/40mL) or =0.75oz alcohol)
  6. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (1 caffeine unit is contained in the following items: one 6oz (180mL) cup of coffee, two 12oz (360mL) cans of cola, one 12oz cup of tea, three 1oz (85g) chocolate bars. Decaffeinated coffee, tea, or cola are not considered to contain caffeine)
  7. Current use of any medication (including over-the-counter, herbal, or homeopathic preparations) with the exception of female hormonal replacement therapy or hormonal . Occasional use of over-the-counter doses of ibuprofen or acetaminophen for minor self-limited pain (eg, headaches) is also acceptable. Current use is defined as use within 7 days of the first dose of product\
  8. Pregnant or lactating females
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Icatibant (30 mg)

    30mg dose of icatibant is administered as a single subcutaneous injection in the abdominal area

    Drug: Icatibant (30 mg)

Interventions

  • On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments

    Also known as: Firazyr

06

What researchers measure

Primary outcomes

  1. Peak Plasma Concentration (Cmax) of Icatibant and Metabolites

    Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

    Time frame: Over 48 hours post-dose

  2. Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites

    Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

    Time frame: Over 48 hours post-dose

  3. Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites

    The time it takes for the blood plasma concentration of a substance to halve.

    Time frame: Over 48 hours post-dose

  4. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites

    AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Over 48 hours post-dose

  5. Total Body Clearance (CL/F) of Icatibant

    The rate at which a drug is removed from the body.

    Time frame: Over 48 hours post-dose

  6. Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites

    AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

    Time frame: Over 48 hours post-dose

Secondary outcomes

  1. The Total Number of Treatment-Emergent Adverse Events

    Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.

    Time frame: TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration

  2. The Percentage of Subjects With Any Injection Site Reactions.

    Time frame: Over 48 hours post-dose

  3. Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results

    Time frame: Over 48 hours post-dose

  4. Change From Baseline in Diastolic Blood Pressure

    Time frame: Over 48 hours post-dose

  5. Change From Baseline in Systolic Blood Pressure

    Time frame: Over 48 hours post-dose

  6. Change From Baseline in Pulse Rate

    Time frame: Over 48 hours post-dose

07

Results

Posted Jan 14, 2015

Participant flow

Participant flow — Overall Study
MilestoneIcatibant (30 mg)
Started12
Completed12
Not completed0

Outcome measures

PrimaryPeak Plasma Concentration (Cmax) of Icatibant and Metabolites

Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated.

Time frame:
Over 48 hours post-dose
Reported as:
Mean · ng/mL
Peak Plasma Concentration (Cmax) of Icatibant and Metabolites
ng/mLIcatibant (30 mg)
Icatibant1190 ± 261
Metabolite 1340 ± 67.7
Metabolite 2365 ± 74.8
PrimaryTime to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites

Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached.

Time frame:
Over 48 hours post-dose
Reported as:
Mean · hr
Time to Peak Plasma Concentration (Tmax) of Icatibant and Metabolites
hrIcatibant (30 mg)
Icatibant0.67 ± 0.20
Metabolite 11.92 ± 0.289
Metabolite 21.92 ± 0.289
PrimaryDrug Concentration Half-Life (T1/2) of Icatibant and Metabolites

The time it takes for the blood plasma concentration of a substance to halve.

Time frame:
Over 48 hours post-dose
Reported as:
Mean · hr
Drug Concentration Half-Life (T1/2) of Icatibant and Metabolites
hrIcatibant (30 mg)
Icatibant1.77 ± 0.356
Metabolite 13.69 ± 0.579
Metabolite 24.11 ± 1.01
PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites

AUCinf is the area under the plasma concentration versus time curve extrapolated from time 0 to infinity, calculated using the observed value of the last non-zero concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Over 48 hours post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Infinity (AUCinf) of Icatibant and Metabolites
ng*hr/mLIcatibant (30 mg)
Icatibant2320 ± 403
Metabolite 11750 ± 308
Metabolite 21960 ± 346
PrimaryTotal Body Clearance (CL/F) of Icatibant

The rate at which a drug is removed from the body.

Time frame:
Over 48 hours post-dose
Reported as:
Mean · mL/hr
Total Body Clearance (CL/F) of Icatibant
mL/hrIcatibant (30 mg)
Total Body Clearance (CL/F) of Icatibant13200 ± 1890
SecondaryThe Total Number of Treatment-Emergent Adverse Events

Treatment-emergent adverse events (TEAEs) were those that started after the single dose of icatibant.

Time frame:
TEAEs were collected after the single dose of icatibant until follow up, 5-7 days after icatibant administration
Reported as:
Number · Treatment Emergent Adverse Events
The Total Number of Treatment-Emergent Adverse Events
Treatment Emergent Adverse EventsIcatibant (30 mg)
The Total Number of Treatment-Emergent Adverse Events2
SecondaryThe Percentage of Subjects With Any Injection Site Reactions.
Time frame:
Over 48 hours post-dose
Reported as:
Number · percentage of participants
The Percentage of Subjects With Any Injection Site Reactions.
percentage of participantsIcatibant (30 mg)
Erythema100.00
Warm sensation50.00
Swelling91.67
Cutaneous pain33.33
Itching/Pruritus8.33
Burning sensation8.33
SecondarySafety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results
Time frame:
Over 48 hours post-dose
Reported as:
Number · percentage of participants
Safety Evaluation Measured by Percentage of Subjects With Not Clinically Significant Abnormalities in ECG Results
percentage of participantsIcatibant (30 mg)
Screening91.67
Day 1, Pre-dose50.00
Baseline50.00
Day 1, 0.75 hours33.33
Day 1, 8 hours33.33
Day 2, 24 hours66.67
Day 3, 48 hours66.67
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites

AUC0-t is the area under the plasma concentration versus time curve extrapolated from time 0 to to the last quantifiable concentration. AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body.

Time frame:
Over 48 hours post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Icatibant and Metabolites
ng*hr/mLIcatibant (30 mg)
Icatibant2320 ± 402
Metabolite 11740 ± 307
Metabolite 21950 ± 345
SecondaryChange From Baseline in Diastolic Blood Pressure
Time frame:
Over 48 hours post-dose
Reported as:
Mean · mmHg
Change From Baseline in Diastolic Blood Pressure
mmHgIcatibant (30 mg)
Day 1, 0.5 h-2.0 ± 6.42
Day 1, 1 h-3.8 ± 4.30
Day 1, 2 h-5.2 ± 4.57
Day 1, 4 h-5.2 ± 7.52
Day 1, 6 h-4.8 ± 8.07
Day 1, 8 h-4.5 ± 6.67
Day 1, 12 h-3.4 ± 9.06
Day 2, 24 h-1.8 ± 7.76
Day 3, 48 h-5.3 ± 6.18
SecondaryChange From Baseline in Systolic Blood Pressure
Time frame:
Over 48 hours post-dose
Reported as:
Mean · mmHg
Change From Baseline in Systolic Blood Pressure
mmHgIcatibant (30 mg)
Day 1, 0.5 h-1.8 ± 12.07
Day 1, 1 h-1.9 ± 13.03
Day 1, 2 h-5.8 ± 14.21
Day 1, 4 h-7.3 ± 17.06
Day 1, 6 h-4.3 ± 16.20
Day 1, 8 h-3.0 ± 11.52
Day 1, 12 h-4.4 ± 14.11
Day 2, 24 h-6.2 ± 11.98
Day 3, 48 h-6.4 ± 12.72
SecondaryChange From Baseline in Pulse Rate
Time frame:
Over 48 hours post-dose
Reported as:
Mean · beats per minute
Change From Baseline in Pulse Rate
beats per minuteIcatibant (30 mg)
Day 1, 0.5 h1.4 ± 7.53
Day 1, 1 h0.1 ± 5.38
Day 1, 2 h-3.0 ± 9.67
Day 1, 4 h-6.3 ± 9.91
Day 1, 6 h-0.1 ± 11.15
Day 1, 8 h-3.6 ± 10.88
Day 1, 12 h-3.2 ± 10.50
Day 2, 24 h-6.8 ± 9.02
Day 3, 48 h-4.0 ± 9.77

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Icatibant (30 mg)—0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventIcatibant (30 mg)
CostochondritisMusculoskeletal and connective tissue disorders1/12
Injection Site PainGeneral disorders1/12

Baseline characteristics

The Safety Set consisted of all subjects who had taken the single dose of icatibant.

Age, Categorical
Age, Categorical(Participants)Icatibant (30 mg)
<=18 years0
Between 18 and 65 years12
>=65 years0
Age, Continuous
Age, Continuous(years)Icatibant (30 mg)
Mean30.7 ± 8.08
Sex: Female, Male
Sex: Female, Male(Participants)Icatibant (30 mg)
Female6
Male6
Region of Enrollment
Region of Enrollment(Participants)Icatibant (30 mg)
United States12
08

Study locations

1 site
  • PAREXEL
    Glendale, California 91206, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2014 to primary completion in Feb 2014, 0 months.

Results were first posted in Jan 2015, 10 months after primary completion.

Of 13 phase 1 interventional studies under Angioedemas, Hereditary, half reached primary completion within 5 months of starting (the median); a quarter within 4 and three quarters within 9. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2014
First posted
Jan 24, 2014
StartActual
Feb 21, 2014
Primary completionActual
Feb 27, 2014
CompletionActual
Feb 27, 2014
Results first posted
Jan 14, 2015
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02045264
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Jan 24, 2014
Start date
Feb 21, 2014
Primary completion
Feb 27, 2014
Completion
Feb 27, 2014
Results posted
Jan 14, 2015
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion